Delving into the Latest Updates on YL-205 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

YL 205, YL205

Target

NaPi-2b x TOP1

Mechanism

NaPi-2b inhibitors(Sodium-dependent phosphate transport protein 2B inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Suzhou Medilink Therapeutics Ltd.

Active Organization

Suzhou Medilink Therapeutics Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估YL205在局部晚期或转移性实体瘤患者中的安全性，有效性和耐受性；在晚期实体瘤患者中确定YL205的最大耐受剂量、推荐扩展剂量和Ⅱ期推荐剂量（RP2D）。次要目的：评估YL205总抗体、游离毒素以及潜在代谢物的药代动力学特征；评价YL205的免疫原性；初步评价YL205在治疗晚期实体瘤患者中的有效性。

[Translation]

Primary objectives: Evaluate the safety, efficacy and tolerability of YL205 in patients with locally advanced or metastatic solid tumors; Determine the maximum tolerated dose, recommended expansion dose and phase II recommended dose (RP2D) of YL205 in patients with advanced solid tumors. Secondary objectives: Evaluate the pharmacokinetic characteristics of YL205 total antibody, free toxin and potential metabolites; Evaluate the immunogenicity of YL205; Preliminary evaluation of the effectiveness of YL205 in the treatment of patients with advanced solid tumors.

Start Date04 Jun 2024

Sponsor / Collaborator